drugset / Trial / NCT02526381

Clinical Study On The Relation Among Prescription, Syndrome and Disease of Turbid Phlegm and Blood Stasis for Coronary Heart Disease

NCT02526381 ↗

Non-randomizedFactorialOpen-labelTreatment

Summary

Clinical study on patients with turbid phlegm and blood stasis syndrome and Qi -Yin Deficiency syndrome of coronary artery disease (CHD) compared with normal cases will be launched. Detection of lipid metabolism, inflammation medium, endothelial cell injury, blood coagulation function evaluation of the relationship between disease and biochemical basis, detect plasma metabonomics and the gene expression profile chip, with "phlegm - lipid metabolic disorder", "stasis - microcirculation disorder", "alternating knot - inflammation mediated" and other system related to the biological basis. With Danlou Tablet for treatment, the investigators can observe result/effect index of turbid phlegm and blood stasis syndrome. Through comprehensive comparison of multi-level, multi-targets and multi-date biological index to discuss its sickness-syndrome-prescription corresponding relation and its biological basis.

Timeline

Start
2015-07
Primary completion
2017-12
Completion
2018-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Danlou Tablets Traditional medicine (herbal / TCM) 1.5 g Oral
Subject Tongmai Yangxin Pills Unknown 4 g Oral